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II (liraglutide, saxagliptin), depression (agomelatine), bipolar dis-
order (asenapine), and epilepsy (eslicarbazepine). Data of all Phase 
II and III trials were identified in the European public assessment 
reports, the WHO Trials Registry, and PubMed. Outcome measures: 
the number of randomized subjects and the number of those aged 65 
and 75 years and older. Trials with missing data were not included 
in the calculation of that outcome. Rates of trials giving information 
about the number of older subjects and the proportions of older 
people were calculated.
Results: The number of people aged 65+ and 75+ was available in 
39% and 48% of the 116 included trials, respectively. The propor-
tion of older people varied from 0% to 93%. In trials for indications 
primarily related to aging (n = 7), 47.1% of the subjects were 65+ 
(median, 2681; range, 524–5848); 20.6% were 75+ (median, 1575; 
range, 216–5848). In trials for indications not specific for, but present 
in old age (n = 5), 7.5% of the subjects were 65+ (median, 108; range, 
14–887); 0.9% were aged 75 and older (median, 26; range, 0–83).
Conclusion: This study on the number of older subjects in clinical 
trials of recently authorized drugs shows that in trials for indications 
primarily related to aging, almost half of the randomized subjects are 
aged 65 and older. In trials for indications not specific for, but present 
in old age, the number and especially the proportion of older subjects 
is limited. So, serious improvement concerning the inclusion of the 
older target population is needed for drugs intended for younger as 
well as for older patients.
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Introduction: A single inhaled dose of laninamivir octanoate (LO), 
a long-acting neuraminidase inhibitor, exhibits efficacy to treat both 
adult and pediatric patients with influenza virus infection. However, 
the relation between the intrapulmonary pharmacokinetics (PK) of 
LO and laninamivir, an active metabolite, and its long-lasting efficacy 
has not fully been investigated. Intrapulmonary pharmacokinetics 
in healthy volunteers and the intracellular drug disposition in mice 
were evaluated to clarify the potential mechanism for the prolonged 
high intrapulmonary retention of laninamivir, which would support 
its long-lasting efficacy.
Patients (or Materials) and Methods: A single-center, open-label 
study was performed in adult healthy volunteers. Seven subgroups of 
5 subjects each underwent bronchoalveolar lavage (BAL) at specified 
time intervals from 4 to 240 hours after a single inhaled administra-
tion of LO (40 mg). Plasma, BAL fluid, and alveolar macrophage 
(AM) were analyzed to determine laninamivir and LO concentrations 
using validated LC-MS/MS methods. The concentrations in epithe-
lial lining fluid (ELF) were calculated by the urea diffusion method. 
Microautoradiographic localization in the respiratory tissues was 
evaluated after a single intranasal administration of radiolabeled LO 
to mice. In addition, the disposition of LO and laninamivir was evalu-
ated by measuring the drug uptake and release in primary cultured 
mouse airway epithelial cells.
Results: In healthy volunteers, the peak plasma concentrations of 
laninamivir occurred at 3.5 hours after inhalation and decreased 
with the half-life of 45.7 hours. Laninamivir concentrations in ELF 
and AM were much higher than those in plasma and lasted for 240 
hours. Cmax of laninamivir in ELF from first BAL was 8.6 μ g/mL and 
laninamivir in ELF decreased with longer half-life (~6 days) than that 
in plasma. Laninamivir concentrations in ELF notably exceeded the 
IC50 values for viral neuraminidase at all time points examined. In 
mice, the labeled LO derived activity after an intranasal administra-
tion mainly located on the epithelial cells for a long period. The 
uptake of LO in airway epithelial cells increased without any appar-
ent saturation even at the highest concentration tested (1000 μ M). 
Furthermore, the intracellular laninamivir was released very slowly 
into the drug-free medium, which was regarded as a rate-limiting 
step in the cellular retention.
Conclusion: ELF concentration profiles and prolonged high intrapul-
monary retention of laninamivir support its long-lasting efficacy to 
treat patients with influenza virus infection by the single inhalation.
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Introduction: Busulfan, an alkylating agent, is used in combination 
with other drugs in patients undergoing stem cell transplantation. 
Busulfan presents a very narrow therapeutic window, which has been 
linked to various adverse events. Therapeutic monitoring protocols 
have been developed to allow the individualization of the dose, but 
the dose selection and the sampling time for pharmacokinetics are 
based on empirical evidence. Consequently, target exposure cannot be 
warranted. The aim of this investigation was to determine the optimal 
sampling scheme and develop a model-based dosing algorithm for 
busulfan in stem cell transplantation patients.
Patients (or Materials) and Methods: Clinical data (n = 29) from 
an ongoing study were used for the purposes our analysis. A 1-com-
partment model was selected as basis for sampling optimization and 
subsequent evaluation of a suitable dosing algorithm. Internal and 
external model validation procedures were performed before the opti-
mization steps using ED-optimality criteria. Clearance and volume 
of distribution were considered as parameters of interest. The final 
sampling scheme and dosing algorithm were based on the deviation 
from target exposure range, as determined by AUC(0–6).
Results: A 1-compartment model was found to describe busulfan 
exposure after oral administration, with ideal body weight (IBW) 
and alanine transferase (ALT) as covariates on clearance. A sparse 
sampling scheme with five samples per patient (t = 0.5, 2.25, 3, 4, and 
5 hours after dose) was found to be sufficient for the characterization 
